Introduction
Watson Pharmaceuticals (Watson) is the third largest generic pharmaceutical company in the US. The company develops, manufactures, markets and distributes brand and generic pharmaceutical products in various therapeutic areas including central nervous system, nephrology, hormones and synthetic substitutes and cardiovascular.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Watson operates in three business segments: generic, brand, and distribution. It''s 160 generic products include contraceptives, treatment for pain management, depression, hypertension, and smoking cessation indications, as well as oral contraceptives. Currently, the company has 60 abbreviated new drug application (ANDAs) pending at the FDA. The company''s revenues grew at a CAGR of 13% from $1,223 million to $1,979 million during 2002-2006, mainly due to the increased sales of generic oral contraceptives including TriNessa and Trivora; specialty products including Oxytrol and Trelstar; and nephrology products such as Ferrlecit contributed to the product sales.
Watson''s revenues are estimated to increase at an impressive CAGR of 12% from $1,979 million in 2006 to $3,076 million in 2010. The major contributors of revenue will be generic product sales. The company launched 16 generic products in 2007 including bupropion hydrochloride XL, Wellbutrin XL, and Telia Fe.
Reasons to Purchase
Access all the important information and analysis on the company in a single report
Understand company''s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company''s adjusted five year financial data along with key ratios and market capitalization
http://www.companiesandmarkets.com/information.asp?id=5N3YCW4S745900
CONTACT: Mike King, Director, www.companiesandmarkets.com Tel: +44 (0)1933 674 780 Fax: +44 (0)1933 674 780 e-mail: info@companiesandmarkets.com WWW:http://www.companiesandmarkets.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index